Morphosys rises on cooperation agreement with Pfizer, Incyte
14/06/2022 06:54
** Morphosys MORG.DE shares rise 5.1% in Lang & Schwarz
premarket trade after the German biotech group entered
collaboration with Pfizer PFE.N and Incyte INCY.O for the
clinical trial of Morphosys and Incyte's Monjuvi with Pfizer's
TTI-622 urn:newsml:reuters.com:*:nFWN2Y00L3
** The aim of the clinical trials is to investigate the
treatment's effect on patients diagnosed with relapsed or
refractory diffuse large B-cell lymphoma who are not eligible
for autologous stem cell transplantation
** "Good for sentiment even though revenues outcome unclear"
a local trader says
** Morphosys shares stand on top of Germany's smallcaps
index .SDAXI in Lang & Schwarz premarket trade
(Reporting by Tristan Chabba)
((Tristan.chabba@thomsonreuters.com))